ICU

0.935010.95%
MM

Michael Messinger

Chief Financial Officer

Mr. Michael Messinger, also known as Mike, C.P.A. is Chief Financial Officer at SeaStar Medical Holding Corporation since November 14, 2025. He has been Independent Director of Filament Health Corp. since March 2024. He served as President and Chief Executive Officer at ContraFect Corporation since November 15, 2023 until December 04, 2023. He had been Chief Financial Officer of ContraFect Corporation since November 12, 2018 until December 04, 2023 and served as its Chief Accounting Officer until December 04, 2023, respectively. Mr. Messinger served as Chief Financial Officer of ContraFect Corporation, where he led company through its Nasdaq IPO in 2014, multiple financing rounds, including investments from Pfizer Inc. and a 90 million contract with BARDA (Biomedical Advanced Research and Development Authority). Prior to joining ContraFect, Mr. Messinger held senior financial roles at Lexicon Pharmaceuticals Inc. and Coelacanth Corporation. He started his career as an auditor at Ernst & Young LLP. Mr. Messinger served as the Senior Vice President of Finance at ContraFect Corporation since October 01, 2016 until November 2018. Mr. Messinger served as the Vice President of Finance at ContraFect Corporation since November 2012 until October 01, 2016 and served as its Chief Accounting Officer until October 01, 2016. Mr. Messinger has experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmaceuticals, Inc since August 2016. In this capacity, he was responsible for the financial management of Lexicon’s partnership with Symphony Capital, LLC, in addition to coordinating fiscal and program management concerning Lexicon’s development programs. He started his career as an auditor at Ernst & Young, LLP. He received his B.B.A degree in accounting from the University of Michigan.

Positions